

1806

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

ATTORNEYS AT LAW

FOURTH FLOOR

1755 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202 U. S. A.

TELEPHONE
(703) 413-3000
FACSIMILE
(703) 413-2220
INTERNET

OBLONPAT@OBLON.COM

MCI MAIL

367-6411

TELEX
248855 OPAT UR


PATENT, TRADEMARK AND COPYRIGHT LAW
AND RELATED FEDERAL AND ITC LITIGATION

WEST COAST OFFICE

224 AIRPORT PARKWAY, SUITE 300
SAN JOSE, CALIFORNIA 95110

TELEPHONE
(408) 436-2070
FACSIMILE
(408) 436-2075

*BAR MEMBERSHIP OTHER THAN VIRGINIA
*REGISTERED PATENT AGENT



NORMAN F. OBLON
MARVIN J. SPIVAK
C. IRVIN McCLELLAND
GREGORY MAIER
ARTHUR I. NEUSTADT
RICHARD D. KENNY
JAMES D. HAKKIO
ECKHARD H. KUNZ
ROBERT T. POUS
DAVID J. KERA
CHARLES L. GHOLZ
VINCENT J. SUNDERDICK
WILLIAM E. BEAUMONT
STEVEN B. KELBER
STUART O. DWORK
ROBERT F. GNUSE
JEAN-PAUL LAVALLEE, PH.D.
JEFFREY H. KAUFMAN
BRIAN D. ANDERSON
ROBERTA S. BREN
WILLIAM B. WALKER
TIMOTHY R. SCHWARTZ, PH.D.
JOHN H. WEBER
STEPHEN G. BAXTER, PH.D.
GILBERTO M. VILLACORTA, PH.D.
NEIL D. GREENSTEIN

ALTON D. ROLLINS
JOHN H. O. CLARKE
JAMES R. BOLER
JOHN T. GOOLKABIAN
JOHN A. NOVAIS
DAVID M. ZOLTICK
CARL E. SCHLIER
STEVEN P. WEIHRUCH
P. JAY HINES
BARRY P. MILLER
SURINDER SACHAR
JAMES J. KULBASKI
TIMOTHY L. SCOTT
CATHERINE B. RICHARDSON
JOHN C. BROSKY
MARC ASPERAS
ROBERT W. HAML, PH.D.
JONATHAN HUDIS
RICHARD A. NEIFELD, PH.D.
RICHARD L. TREANOR, PH.D.
FREDERICK O. VASTINE, PH.D.
MURRAY TILMAN
RICHARD L. CHINN, PH.D.
ANDREW D. FORTNEY, PH.D.
MARC R. LABGOLO, PH.D.
J. DEREK SHANNON, PH.D.
KAREN L. SHANNON, PH.D.
DAVID H. VANCE, PH.D.
PAUL E. RAUCH, PH.D.

MILTON STERMAN
SAMUEL H. BLECH
JOHN O. TRESANSKY

Docket No. 18-859-0 PCT

HON. COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231

RE: Application Serial No.: 08/295,782
Applicant(s): Hitoshi NISHIYAMA, et al.
Filed: September 12, 1994
For: DEPSIPEPTIDE DERIVATIVE, PRODUCTION
THEREOF AND USE THEREOF

ATTN: APPLICATION PROCESSING DIVISION, SPECIAL
PROCESSING AND CORRESPONDENCE BRANCH

SIR:

Attached hereto for filing are the following papers:

RESPONSE TO NOTICE TO COMPLY...ACID SEQUENCE DISCLOSURES
CITED REFERENCE (1)
NOTICE TO FILE MISSING PARTS
NOTICE TO COMPLY

Our check in the amount of \$ -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 CFR 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

David H. Vance
Norman F. Oblon
Attorney of Record
Registration No. 24,618

Crystal Square Five
Fourth Floor
1755 Jefferson Davis Hwy.
Arlington, VA 22202
(703) 413-3000


David H. Vance, Ph.D.
Registration No. 38,644

#5
Let. re: Seq. Dtd.
w/ ref. 2-14-95

RECEIVED
FEB 21 1995
GROUP 1800
1806
Russett
1811

feature note) is embraced by the definition of an amino acid sequence. However, Applicants note that the sequences in the above-identified application are not included in the definition of an amino acid sequence given by 37 C.F.R. § 1.821.

The present invention relates to depsipeptide derivatives represented by the following formula (I):



Formula (I) contains alternating amino acid (moieties containing substituents D and B) and lactic acid (moieties containing substituents A, A^a and C) groups. The structure of lactic acid is shown by formulas (24) and (25) on page 95 of J. March, ADVANCED ORGANIC CHEMISTRY (1985), attached herewith. Lactic acid is not an amino acid, but rather an α -hydroxy acid, and therefore, can not be represented by any of the three-letter amino acid abbreviations given in 37 C.F.R. § 1.822(b)(2). As a result, the depsipeptide shown by formula (I) does not contain a sequence of four or more amino acids or any peptide or protein that can be expressed as a sequence using the symbols in 37 C.F.R. § 1.822(b)(2).


Furthermore, all of the other depsipeptides shown in the text of the above-identified application contain structures similar to that of Formula I, i.e., alternating amino acid and lactic acid. Accordingly, the sequences disclosed in the

above-identified application are not subject to the requirements of 37 C.F.R. §§ 1.821-1.825, and withdrawal of this requirement is respectfully requested.

In view of the foregoing, Applicants submit that the application is now in condition for examination on the merits. Early notification of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

David H. Vance, Ph.D.
Registration No. 38,644

Crystal Square Five - Fourth Floor
1755 Jefferson Davis Highway
Arlington, VA 22202
(703) 413-3000
DHV/cle/esu